Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05976373 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT05976373 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 38 participants.
The verdict
NCT05976373, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a phase 1, single subcutaneous dose study to evaluate safety and pharmacokinetic of 2 different dupilumab drug products in adult healthy volunteers. The duration per participant is up to 11 weeks.
Interventions
- DRUG Dupilumab (SAR231893)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2015-01-05 |
| Est. Completion | 2015-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05976373
The ClinicalTrials.gov registry entry for NCT05976373 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab (SAR231893) is the first listed.
NCT05976373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05976373 about?
NCT05976373 is a clinical study titled "A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.". This is a phase 1, single subcutaneous dose study to evaluate safety and pharmacokinetic of 2 different dupilumab drug products in adult healthy volunteers. The duration per participant is up to 11 weeks.
What is the current status of trial NCT05976373?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2015-01-05. Estimated completion is 2015-03-30.
What interventions are being tested in trial NCT05976373?
The interventions under investigation include: Dupilumab (SAR231893) (DRUG).
Who is sponsoring clinical trial NCT05976373?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.